combination therapy

Research in Review
Triplet Combination Shows Long-Term Efficacy in Advanced Multiple Myeloma
06/26/2017
JCP Editors
Combination therapy involving a novel treatment is associated with reduced risk of death and improved progression-free survival (PFS) in patients with advanced multiple myeloma, according to research presented at the...
Combination therapy involving a novel treatment is associated with reduced risk of death and improved progression-free survival (PFS) in patients with advanced multiple myeloma, according to research presented at the...
...
06/26/2017
Journal of Clinical Pathways
Research in Review
Adding Targeted Therapy Improves CAR-T Response Rates in CLL
06/15/2017
JCP Editors
Researchers report significantly improved response rates in patients with chronic lymphocytic leukemia (CLL) treated with concurrent targeted therapy and chimeric antigen receptor T-cell (CAR-T)...
Researchers report significantly improved response rates in patients with chronic lymphocytic leukemia (CLL) treated with concurrent targeted therapy and chimeric antigen receptor T-cell (CAR-T)...
...
06/15/2017
Journal of Clinical Pathways
Research in Review
Brain Metastases Resistant to Targeted Therapy Due to Gene Overexpression
06/14/2017
JCP Editors
A novel mechanism responsible for brain metastasis resistance to targeted therapy has been identified, which may help guide treatment strategies, according to a study published in Science Translational Medicine...
A novel mechanism responsible for brain metastasis resistance to targeted therapy has been identified, which may help guide treatment strategies, according to a study published in Science Translational Medicine...
A...
06/14/2017
Journal of Clinical Pathways
Research in Review
Combination Therapy Improves Outcomes for Patients With MCL
06/08/2017
JCP Editors
Patients with mantle cell lymphoma (MCL) have increased odds of achieving complete remission after being treated with a combination regimen, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...
Patients with mantle cell lymphoma (MCL) have increased odds of achieving complete remission after being treated with a combination regimen, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...
...
06/08/2017
Journal of Clinical Pathways
Research in Review
Metastatic Hormone-Naïve Prostate Cancer Effectively Treated With Combination Therapy
06/07/2017
JCP Editors
Groundbreaking results of a trial have shown that the combination of a new drug with androgen deprivation therapy (ADT) significantly improves overall survival (OS) and radiographic progression-free survival (PFS) in...
Groundbreaking results of a trial have shown that the combination of a new drug with androgen deprivation therapy (ADT) significantly improves overall survival (OS) and radiographic progression-free survival (PFS) in...
...
06/07/2017
Journal of Clinical Pathways
Research in Review
Triple Combination Active in High-Risk B-Cell Malignancies
05/24/2017
JCP Editors
A combination of 3 pathway inhibitors is well tolerated with activity observed in heavily pre-treated and high-risk B-cell malignancies, according to research that will be presented at the ASCO Annual Meeting (June...
A combination of 3 pathway inhibitors is well tolerated with activity observed in heavily pre-treated and high-risk B-cell malignancies, according to research that will be presented at the ASCO Annual Meeting (June...
A...
05/24/2017
Journal of Clinical Pathways
Research in Review
Lenalidomide Maintenance Prolongs PFS in Older Patients With Diffuse B-Cell Lymphoma
05/12/2017
JCP Editors
Lenalidomide maintenance therapy for 24 months after obtaining a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large...
Lenalidomide maintenance therapy for 24 months after obtaining a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large...
...
05/12/2017
Journal of Clinical Pathways
Research in Review
Combination Therapy Effective in Treating Chemo-Resistant Ovarian Cancer
05/09/2017
JCP Editors
A combination regimen involving standard carboplatin chemotherapy and a novel drug may improve overall survival for more than 50% of women with high-grade serous ovarian cancers, according to research published in...
A combination regimen involving standard carboplatin chemotherapy and a novel drug may improve overall survival for more than 50% of women with high-grade serous ovarian cancers, according to research published in...
A...
05/09/2017
Journal of Clinical Pathways
Research in Review
Lenalidomide Maintenance Prolongs PFS in Older Patients With Diffuse Large B-Cell Lymphoma
04/28/2017
JCP Editors
Lenalidomide maintenance therapy for 24 months after a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large B-cell...
Lenalidomide maintenance therapy for 24 months after a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large B-cell...
...
04/28/2017
Journal of Clinical Pathways
Research in Review
Palbociclib Plus Fulvestrant Improves PFS in Type of Breast Cancer
04/19/2017
JCP Editors
Adding palbociclib to fulvestrant prolongs progression-free survival (PFS) compared with fulvestrant alone among pre- and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor...
Adding palbociclib to fulvestrant prolongs progression-free survival (PFS) compared with fulvestrant alone among pre- and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor...
Adding...
04/19/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use